The Calton described horrors are mostly in the other drugs. Glad to hear you find Tymlos helpful.
But since you asked . . .
This excerpt (please excuse my typos) is from the Calton 2019 "Build Your Bones" book, page 34-5 that ..."Abaloparatide is a newcomer to the osteoporosis drug market, approved by the FDA in 2017. It's a small tweak on teriparatide that the pharmaceutical companies are hoping brings them a big monetary reward. Because of their chemical similarities, these two drugs have similar adverse effects. However, there are some pluses and minuses to choosing abaloparatide vs teriparatide. First, and this is a plus, our odds of getting hypercalcemia are less. On the mnus side, although the initial increases in the bone formation marker were similar for abaloparatide and teriparatide within the first month, by month three, bone formation began to decrease in the abaloparatide group compared with the teriparatide group. Basically, it's not as good at building bone. Both cause plausible increases in cortisol and calcium levels, as well as decreases in cognition and magnesium levels. Here again, the main issue is cancer. . .